IMUX — Immunic, Inc.

Company context · prepared 2026-08-11 · company sweep 2026-08-11 · USD · framework v5.6.1

How to read this. Written for a reader who has not studied pharmacology or finance. General terms are defined once in framework/04-glossary.md. Tags: [VERIFIED — source] / [UNVERIFIED] / [WEB ESTIMATE — source, date].

Program analyses for this company are the sub-folders listed in C.2.

C.0 Company-tier coverage — CLEARED

No mandatory company-tier row reads NOT CALLED and none reads BLOCKED, so the company tier is cleared. The one NOT CALLED row above is an optional connector, which does not gate anything.

C.1 What the company is

Immunic, Inc. is a clinical-stage biotechnology company headquartered in New York with research operations in Gräfelfing, Germany. It develops tablets taken by mouth for chronic inflammatory and autoimmune diseases, and it has no product revenue [VERIFIED — BPIQ fetch_company_info 2026-08-11, which reports no revenue line; Q1 2026 Form 10-Q, filed 2026-05-13].

The company is effectively a single-asset company. Its pipeline feed returns eight program rows, and six of the eight are the same molecule, vidofludimus calcium (also called IMU-838), in different diseases [VERIFIED — BPIQ fetch_company_drugs 2026-08-11]. Exactly one of those eight rows carries a disclosed catalyst: the Phase 3 readout of that molecule in relapsing multiple sclerosis. Of the other seven, two are marked failed and discontinued, one has been shelved pending a partner, one is under strategic review pending financing or partnering, one holds the completed Phase 2 evidence base for the lead program, and one is a follow-on multiple sclerosis program that only starts if the lead readout works.

Both the capital structure and the management changed substantially during 2026. The company raised $200 million gross in a private placement in February 2026, executed a 1-for-10 reverse stock split in April 2026, and replaced its chief executive, its chief medical officer and its board chair between April and July 2026 [VERIFIED — Q1 2026 Form 10-Q and the company press-release feed; see C.3 and C.5].

The single most important number on this page is that the market capitalisation most data services publish counts only the 13.6 million common shares in issue and ignores 22.9 million pre-funded warrants that were paid for in full in February 2026. A pre-funded warrant is a right to buy a share that has already been paid for, leaving only a token $0.001 due on exercise, so it is economically a share that already exists. On the economic share count the company is worth roughly $515 million, not the $195 million the connector reports. C.4 does that arithmetic.

C.2 Pipeline — every program

Six of the eight rows are the same molecule. Its name is recorded inconsistently across those rows, including a trailing space on "Vidofludimus calcium (IMU-838) ", which is the connector bug that makes the integer bpiq_drug_id the only safe key.

One consequence of this table is worth stating on its own, because it is unusual in this corpus: only one row has has_catalyst: true, so the catalyst-clustering pass has nothing to pair row 16219 against and returns CLEAN with an empty conflict list. On this ticker a price move inside the readout window is attributable to the readout, because there is nothing else on the pipeline that could be causing it.

C.3 Financial position

Dilution history. Immunic’s share count and capital structure changed fundamentally in 2026, and the change is not visible in the headline market-capitalisation figure. Read this table together with C.4.

The February 2026 financing was led by BVF Partners with participation from Aberdeen, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson, OrbiMed, RA Capital, TCGX, Trails Edge, Vivo Capital and Woodline Partners [VERIFIED — company release 2026-02-13].

Is a raise likely before the next catalyst? Probably not, but the previous version of this document was too categorical, and the correction matters. Immunic holds roughly $138M against a readout expected around the end of 2026, so it does not need money to reach the event. But it has $80.0M of undrawn at-the-market capacity inside a $250.0M shelf, which it has simply chosen not to use — that is a standing option to sell stock into strength at ten days’ notice, not an absent mechanism. The larger structural point is unchanged: the relevant dilution has already happened, and a further $200M of it fires automatically on a positive readout. The trap on this ticker is not a surprise financing; it is that the market-capitalisation figure most data services publish understates how much equity is already outstanding by roughly two thirds.

C.4 Valuation frame

This is the run-up baseline for every program under this ticker. Unlike the version of this document written on 2026-08-04, it is derived from the committed daily price cache rather than captured from a connector field, so it can be recomputed for any past date.

A caveat on the price cache itself. data/prices/IMUX.json was last fetched on 2026-08-06 and its final bar is 2026-08-05. It therefore does not cover the three trading sessions before this sweep. The 52-week range is unaffected — neither extreme is recent — but the position within the range is computed off a close five days old, which is why the live BPIQ quote is reported beside it rather than substituted for it. Refreshing the cache is scripts/fetch-prices.mjs’s job and sits outside an analysis run.

A reader who takes the published $195M market capitalisation against $187M of cash concludes that the market values Immunic’s entire pipeline at almost nothing. That conclusion is wrong, and it is the single largest trap on this ticker. On the economic share count the market values the pipeline at roughly $377M. The sell side reached the same conclusion independently: H.C. Wainwright cut its price target on 2026-03-02 with the stated reason being share count changes [WEB ESTIMATE — Investing.com, "H.C. Wainwright cuts Immunic stock price target on share count changes", 2026-03-02, via the BPIQ press feed].

C.5 Ownership and flow

Three new 5%-plus holders have disclosed since the last sweep, and none of them is a biotech specialist. The EDGAR filing feed carries three Schedule 13G or 13G/A filings in the four weeks to 2026-08-06:

• Millennium Management (through Integrated Core Strategies (US) LLC, with Millennium Group Management and Israel A. Englander as joint filers) — 969,547 shares, 7.1% of the common stock, filed 2026-08-06;
• Laurion Capital Management (with Benjamin Alexander Smith and Janaka Sheehan Maduraperuma) — 839,526 shares, 6.2%, filed 2026-08-04;
• Aberdeen Group plc / abrdn Inc. — 824,393 shares, 6.1%, filed 2026-07-16.

[VERIFIED — EDGAR primary_doc.xml for accession numbers 0001104659-26-092235, 0001390202-26-000013 and 0001716774-26-000017; percentages recomputed against the 13,621,526 filed share count]

Together that is 2,633,466 shares, or 19.3% of the common stock, disclosed in under a month. Two of the three are multi-strategy funds rather than long-only biotechnology investors, which is the positioning pattern you would expect ahead of a dated binary event rather than a view on the science. The press feed separately records OMERS Administration Corp opening a position on 2026-08-02 [WEB ESTIMATE — MarketBeat via the BPIQ press feed, 2026-08-02].

Insider flow: grants, not purchases, and nothing new. There has been no open-market purchase by any insider since 2025-06-13, and no insider transaction of any kind since 2025-07-05 [VERIFIED — BPIQ fetch_company_insider_transactions, 250 rows read in full]. The last cluster of open-market buying was in May and June 2025 at prices between $0.56 and $0.83 before the reverse split, equal to $5.60 to $8.35 after it.

Every insider transaction recorded during 2026 is a grant of stock options at a zero recorded transaction price. There are seventeen such grants totalling 2,522,440 options, in four batches:

• 2026-04-24 — 300,000 to the incoming chief medical officer, Michael A. Panzara, at an $8.80 strike;
• 2026-05-22 — 1,000,000 to the incoming chief executive, Erik Lundgren;
• 2026-06-29 — 1,095,590 across ten recipients on the day of the annual meeting, including 445,000 to founder and former chief executive Daniel Vitt, 253,000 to president and chief operating officer Jason Tardio, 120,000 to chief financial officer Glenn Whaley and 100,000 to incoming board chair Michael W. Bonney;
• 2026-07-05 — 126,850 across five directors at a $14.80 strike.

[VERIFIED — BPIQ fetch_company_insider_transactions, cross-checked against the EDGAR Form 4 filing dates of 2026-04-29, 2026-06-01, 2026-06-29 and 2026-07-07; strike prices from the company press feed 2026-06-02 and 2026-07-07]

The honest read. This is routine incentive compensation for a newly installed management team, not conviction buying, and it says nothing directional about the readout. Its size is worth noting even so: 2,522,440 options is about 18.5% of the 13.6 million common shares outstanding, though only about 6.9% of the 36.5 million economic share count. The gap between those two percentages is the same measurement problem C.4 describes, and it cuts in the company’s favour here.

One governance fact a reader weighing independent expert opinion should know. Richard A. Rudick, an Immunic director who received option grants on 2026-06-29 and 2026-07-05, is a long-standing multiple sclerosis methodologist who continues to publish on MS diagnostic criteria — he is a co-author of a 2026-03-10 paper in Multiple Sclerosis and Related Disorders with Gavin Giovannoni and Gary Cutter [VERIFIED — PubMed, DOI 10.1016/j.msard.2026.107132, affiliation given as Astoria Biologica Inc.]. He is not an investigator on ENSURE and expresses no view on it, so he appears in neither table of the program document’s KOL section; he is named here because a reader assessing whose voice in this field is independent of Immunic should be able to see the relationship.

Concentration. The disclosed hedge-fund holdings are thin, and the connector reports only three holders [VERIFIED — BPIQ fetch_company_info, hf_holding_count 3]. Reading them requires the filing-quarter correction described in C.8, so every block below is restated to the quarter it actually holds. BVF Partners held 8,902,972 pre-split shares through the quarter ended 2025-06-30 and 7,652,972 from the quarter ended 2025-09-30 onward, a reduction of 1,250,000 pre-split shares. Ikarian Capital has trimmed steadily, from 1,614,170 shares at 2024-12-31 to 674,662 at 2026-03-31. RTW Investments held 4,567,717 shares through 2024-12-31, 402,107 at 2025-06-30 and nothing thereafter, so it exited across the first half of 2025. ADAR1 Capital Management appears for the first time in the block holding 2026-03-31, with 30,000 shares. [VERIFIED — BPIQ fetch_company_hedge_fund_holdings, 18 blocks; every quarter attribution confirmed by dividing value by shares and matching the result against the committed price cache, see C.8]

All of those figures are pre-split share counts. The important caveat is unchanged: BVF led the $200M February 2026 placement and took it largely in pre-funded warrants, which no 13F common-stock line captures, so BVF’s true economic position is far larger than the number above.

C.6 Options chain and its readability

Plain takeaway: the options chain cannot price this event and should not be used to. There is no listed expiry inside the readout window at all. Three of the four listed expiries — August, September and October 2026 — all fall before the window opens. Only January 2027 spans it, and across that entire expiry there are 568 open call contracts and 13 open put contracts. That is about 58,100 shares of notional exposure against 13.6 million shares outstanding, or 0.4% of the common stock. Any implied move read off it is a quote artefact, not a market view.

The floor artifact is present in this chain and is worth naming as a live example: the 2026-08-21 puts at the $20, $22.50, $25 and $30 strikes and the 2026-09-18 puts at $25 and $30 all carry an implied volatility of exactly 0.01488, the documented floor value. All six are treated as null rather than read. The deep in-the-money August calls carry the opposite artefact in a milder form — the $2.50 call shows an implied volatility of 897% against a $4.00-wide bid–ask spread — and are treated the same way.

C.7 Reaction to past catalysts

Read the correction before the table. The previous version of this document built this section on BPIQ’s intra_day_price_change_percent field. That field does not reconcile with the committed daily price cache on any row, and on two rows it reverses the sign of the day. Every move below is therefore recomputed from data/prices/IMUX.json, which is split-adjusted throughout, and BPIQ’s own figure is shown beside it so the disagreement is visible rather than silently resolved. C.8 records the bug.

The pattern that emerges once the field is corrected is a consistent one, and it is unflattering. On five of the six rows the cache can measure, the stock opened higher on the news and finished the day below its opening print. On the one row that is a read on ENSURE itself, it gave back the entire opening gap and closed down nearly 10%. Whatever this ticker does with good news, holding the opening move is not it.

A limit on the press-feed cross-check. It only works where the feed has items. The feed holds 283 items, of which 228 fall in 2026 and 41 in 2025, leaving 7 in 2024, 2 in 2023, 4 in 2022 and 1 in 2021. For every row above except 2026-02-04, “no confounding announcement found” would mean “the feed holds almost nothing at all for that year”, which is not a check that passed. The rows are marked accordingly rather than smoothed over.

None of these is a Phase 3 primary readout. Every row is a Phase 1 or Phase 2 result, a biomarker, or a blinded committee’s procedural recommendation. There is no precedent anywhere in this company’s history for how it trades on a registrational efficacy result, and that is a real limit on using C.7 to calibrate the coming event. The most that can be said is that the largest close-to-close data-driven move it has ever produced is +11.2%, and the largest intraday excursion is +29.9%, both on the same day.

One further caveat. All the moves above are percentages computed from a split-adjusted series, so they are unaffected by the 1-for-10 reverse split, but any price level quoted in an underlying source published before 2026-04-27 is not. And the press feed carries a headline dated 2026-04-27, “Immunic drops after mid-stage trial data for multiple sclerosis drug”, on the exact day the reverse split took effect; any price read on that date from a third-party source is confounded and is not used here.

C.8 Company data-quality flags

• intra_day_price_change_percent on fetch_company_historical_catalysts is not usable on this ticker, and on one row it reverses the sign of the day. This is the largest finding of this sweep. Checked against the committed, split-adjusted price cache on all seven rows the cache covers, the field matches no simple measure — not open-to-close, not close-to-close, not high-to-open, not high-to-previous-close. On 2024-10-22 it reports +21.2% for a session in which the stock opened at $17.00 and closed at $14.00, which is −17.7% open-to-close and −9.7% close-to-close. On 2023-04-05 it reports +22.5% for a session that closed 10.4% below its own open. C.7 is recomputed from the cache throughout. [Rule 6 and rule 11 both apply.]
• open_price_gap_percent is exact on this ticker, which is the opposite of what the standing connector documentation says. framework/02-connectors.md records this field as unreliable and directs a reader to prefer intra_day_price_change_percent. On all seven IMUX rows the gap field reproduces (open − previous close) ÷ previous close against the price cache to five decimal places, while the field it directs you to is the broken one. Recorded here as a dated observation on one ticker; changing the connector documentation is a framework edit and sits outside an analysis run.
• Enterprise value of $8.56M is not usable and must not be passed through. The connector computes it from a market capitalisation that counts only the 13.6M common shares while ignoring 22.9M fully paid pre-funded warrants. Taken at face value it says the market prices Immunic’s entire pipeline at $9M, which is false. Recomputed on economic shares, enterprise value is roughly $377M. This remains the single largest data trap on this ticker. [Rule 6 and rule 11 both apply.]
• max_52_week_position reproduces the documented previous-close bug exactly, again. The reported 0.85714 is recovered to five decimal places by substituting the previous close of $14.30 into (14.30 − 5.06) ÷ (15.84 − 5.06). Since v5.1.0 this field is not read at all: C.4 derives both the range and the position from the price cache with lib/prices.mjs.
• market_cap uses the previous close as well. $194,787,216 ÷ $14.30 = 13,621,484, within two shares of the EDGAR-filed 13,621,526, while dividing by the last price of $14.10 gives no recognisable figure. The same bug therefore affects two fields, not one.
• The connector’s burn figures disagree with the company’s filed accounts by roughly a factor of two. BPIQ reports a quarterly burn of $17.301M and a monthly burn of $5.767M, while the filed Q1 2026 accounts report $33.235M of operating expense and a $32.588M net loss for the same quarter. Two filed figures agree with each other and disagree with the connector. The recomputed figure is used throughout, and all three are shown in C.3.
• The v5.6.1 hedge-fund filing-quarter bug is confirmed exactly on this ticker, and it corrects a claim the previous version of this document made. Every block is labelled by filing quarter, so its holdings are one quarter older than the label says. Dividing value by shares and matching against the price cache proves it to the cent: the block labelled 2026Q2 implies $1.1099 per pre-split share, or $11.10 post-split, which is the 2026-03-31 close exactly; 2026Q1 implies $5.34, the 2025-12-31 close exactly; 2025Q4 implies $8.82, the 2025-09-30 close exactly. The previous version of this document read the 2026Q2 block as “the roughly $11 post-split price in June 2026”; the June 2026 close was $15.37, and $11.10 is the March close. Every quarter attribution in C.5 is shifted back one block accordingly.
• ADAR1 Capital Management is reported with 30,000 shares and a value of zero. A position cannot have a zero market value, so the value field is an artefact and the position is too small to matter either way.
• Insider transaction prices are not split-adjusted. The May and June 2025 open-market purchases are recorded at $0.56 to $0.83; those are pre-split prices and have been converted in C.5.
• short_float units remain unconfirmed per the standing connector documentation. Since v5.6.0 this document does not rely on it: the FINRA short count divided by the EDGAR-filed share count gives 10.4%, a figure whose units are known, and BPIQ’s 12.2% is reported beside it as a disagreement rather than resolved.
• Drug names in the pipeline feed are dirty, including a trailing space on "Vidofludimus calcium (IMU-838) " and three further spellings of the same molecule. Programs are keyed on the integer bpiq_drug_id throughout, never on the name.
• Third-party price-target aggregators mix pre-split and post-split figures and must not be passed through. A web search run during this sweep returned, for the same ticker on the same day, an average target of $42.40 with a $70.00 high, and an average of $4.80 with a $7.00 high. The second set is the pre-split consensus; the first is a partial and inconsistent conversion of it. A feed item dated 2026-05-08 reads “Immunic (IMUX) price target increased by 920.41% to 54.64”, which is a naive multiplication of a stale pre-split figure. All of these are rejected under rule 6. Only named, dated, post-split broker actions are used, and they are listed in the program document.
• Pre-split analyst targets are not converted and carried forward, even though the arithmetic is trivial. Guggenheim initiated at a $7.00 target on 2026-03-24 and H.C. Wainwright reiterated $8.00 on 2026-02-09; multiplied by ten those are $70 and $80 post-split, three times the highest post-split target any broker has published. H.C. Wainwright’s own 2026-03-02 cut, whose stated reason was share count changes, is the evidence that those targets were struck on a share count that ignored the pre-funded warrants. They are named here and excluded rather than converted.
• Q2 2026 results had not been published as of this sweep. The most recent financial statement is Q1 2026, filed 2026-05-13. EDGAR carries no Q2 2026 Form 10-Q as of 2026-08-11, and the filing deadline is approximately 2026-08-14. Every cash figure dated after 2026-03-31 in C.3 is modelled, not reported, and the next reiteration of the readout guidance is days away.